Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
  1. Home
  2. Products
  3. 5000341036

Medchemexpress LLC Foropafant | 136468-36-5 | 99.9% | 50 MG
SDP

Catalog No. 5000341036
Encompass_Preferred

Foropafant (SR27417) is a highly potent, competitive, selective, and orally active antagonist of the platelet-activating factor (PAF) receptor. It exhibits a Ki value of 57 pM for [3H]PAF binding, which is at least 5-fold lower than that of unlabeled PAF itself, and potently inhibits PAF-induced aggregation of rabbit and human platelets. This product is for research use only.

  • Highly potent
  • Competitive, selective, and orally active antagonist of the platelet-activating factor (PAF) receptor
  • Ki value of 57 pM for [3H]PAF binding
  • Potently inhibits PAF-induced aggregation of rabbit and human platelets
  • Intended for research use only

Catalog No. 50-003-41036 Supplier Medchemexpress LLC Supplier No. HY12869450MG
May include imposed supplier surcharges.
Add to Cart
Add to Cart

missing translation for 'validMainframeMsg'

Foropafant (SR27417) is a highly potent, competitive, selective, and orally active antagonist of the platelet-activating factor (PAF) receptor. It exhibits a Ki value of 57 pM for [3H]PAF binding, which is at least 5-fold lower than that of unlabeled PAF itself, and potently inhibits PAF-induced aggregation of rabbit and human platelets. This product is for research use only.

  • Highly potent
  • Competitive, selective, and orally active antagonist of the platelet-activating factor (PAF) receptor
  • Ki value of 57 pM for [3H]PAF binding
  • Potently inhibits PAF-induced aggregation of rabbit and human platelets
  • Intended for research use only

Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.